South Korean wearable robot heads to US

WIRobotics, a robotics manufacturer from South Korea, is set to launch its wearable gait assistance robot in the United States. 

Called WIM (We Innovate Mobility), the wearable exoskeleton, launched last year, features different modes: assist, resist, hike, and slow walk. It comes with a companion mobile application that provides analysis of gait, including speed, agility, and symmetry. The app, powered by AI and big data, can calculate a user's overall gait age and tailor exercise plans.  

WIM, intended for people of all ages, including seniors and patients recovering from lower-body injuries, has been shown to improve user's physical function, such as speed, endurance, and lower-body strength, by up to 78%. 

Founded in 2024, WIRobotics also offers its flagship product, WIBS (We Innovate Back Support), an unpowered back support wearable robot. 

Australia OKs Chinese hand rehab robot 

Another robotics maker, Syrebo from Shanghai, China, has received approval from Australia for its hand rehabilitation robot. 

The company obtained the Therapeutic Goods Administration's certification for its device, which facilitates users' rehabilitation for neurological conditions, hand injuries, or stroke-related impairments. 

Its hand rehabilitation robot has already received clearances in Europe and the United States. The company now plans to secure partnerships across Asia-Pacific to integrate its rehabilitation products into therapeutic programs.

Indian genAI insurtech raises seed fund

Insurance technology startup Consint.AI from India has raised over $500,000 in a seed funding round led by Equanimity Ventures and Seafund. 

The startup, founded in 2020, develops generative AI-based solutions for optimising insurance transactions, mitigating fraud, and streamlining claims generation. 

Consent.AI will use its seed fund to expand across insurance markets in Asia-Pacific, the Middle East and Africa while also enhancing its generative AI models.

Brain mapping AI startup bags $5M 

Another Indian startup, BrainSight AI, has also recently raised $5 million in a pre-Series A funding round led by IAN Alpha Fund. 

Established in 2019, the company offers an AI-powered brain mapping platform that supports clinicians in precisely diagnosing and preparing treatment plans for neuropsychiatric and neuro-oncological disorders. 

BrainSight AI, which Pfizer previously backed, says it will use its fresh funds to enter markets abroad, including Africa, Southeast Asia, and the United States while covering more ground across the Indian health system.